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Production of E1-deleted adenovirus (rAd) vectors requires complementation by E1A and E1B functions provided by the production cell line.
The two cell lines most commonly used for production of rAd vectors, 293 and Per.C6, were derived from human primary cells and contain
contiguous E1A and E1B sequences from the Ad genome. As an alternative system, we tested complementation of rAd vectors using sequential
transfection of individual E1A and E1B expression cassettes into A549 human lung tumor cells, which support highly efficient replication of wild
type adenovirus. We found that E1A function could be complemented in A549 cells by the mutant E1Adl01/07, and that E1B function could be
provided in such cells using only the 55K E1B gene. Production yields in the resulting producer cell line, designated SL0003, were similar to
those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus.
D 2005 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Gene Therapy; Production cells; E1A; E1BIntroduction
Replication defective adenovirus (rAd) vectors have desir-
able features for gene therapy including wide tissue and cell
tropism, the capacity to accommodate large expression
cassettes and high transduction efficiency. In addition, adeno-
virus is well suited for pharmaceutical development as the virus
grows to high specific titers and scalable manufacturing
processes have been established (Huyghe et al., 1995; Shabram
et al., 1997). Production of rAd vectors requires engineered cell
lines that can complement functions removed from the viral
genome. For pharmaceutical development, the vector-cell line
combination also must be amenable to scale-up and provide
material of sufficient quality and purity. In this work, we
describe a new approach to production of rAd vectors based on0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: john.howe@spcorp.com (J.A. Howe).combining selected viral and host functions required for
adenovirus replication.
Replication defective rAd vectors for gene therapy use are
generally deleted for the viral early region 1 (E1). E1 contains
two transcription units, E1A and E1B that encode a number of
proteins that have critical roles in the early and late phases of
the lytic cycle and production of rAd-vectors requires
complementation of these E1 activities. E1A and E1B gene
functions have been extensively characterized [for review see
(Bayley and Mymryk, 1994; Shenk, 1996)]. The first E1-
complementing line, 293, was generated by transfection of
primary embryonic kidney cells using physically sheared
adenovirus 5 DNA (Graham et al., 1977). Genomic analysis
subsequently demonstrated that 293 cells carry an integrated
fragment of the left-hand end of adenovirus genome (bases 1–
4344), containing the E1 region and additional flanking
sequences (Louis et al., 1997).
Although 293 cells produce E1-deleted rAd vectors at
acceptable levels, an undesirable contaminant called replication6) 220 – 230
www.e
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homologous recombination between the rAd vector and the
adenovirus sequences present in the 293 genome (Lochmuller
et al., 1994; Zhu et al., 1999). To reduce the risk of generation
of RCA by homologous recombination, Fallaux et al., 1998
transfected human embryonic retinoblasts with a recombinant
plasmid containing E1 genes, in which the E1A promoter and
E1B polyadenylation sequences were replaced by heterologous
control elements. Deletion of the adenovirus flanking
sequences in the E1 plasmid yielded a cell line, PER.C6,
which does not generate RCA through homologous recombi-
nation when cell line matched rAd-vectors are produced
(Fallaux et al., 1998). However, recent studies have shown
that an atypical form of RCA, called helper-dependent E1-
positive particles, can be formed when non-matched adenoviral
vectors are propagated in PER.C6 cells (Murakami et al.,
2002).
Although both 293 and PER.C6 cell lines have proved
useful tools for production of rAd vectors, consideration of
recent work on oncolytic adenoviruses as well as the
approaches taken in developing retroviral producer cells
suggested an alternative approach to development of
adenovirus production cell lines. Oncolytic adenoviruses
have been developed for cancer therapy, based on the
observation that human tumor cell lines can provide growth
control and anti-apoptotic functions that are normally
supplied by the E1A and E1B genes of adenovirus
(Dobbelstein, 2004). Thus, adenoviruses with specific dele-
tions affecting E1A or E1B can replicate efficiently in
human tumor cell lines, but are defective for growth in
primary cells. For example, dl01/07 virus contains two
deletions in the E1A gene (see Fig. 1) that limit E1A-
induced cell cycle progression and viral replication in
normal cells (Doronin et al., 2000; Howe et al., 2000).
However, dl01/07 can grow as efficiently as wild type virus
in several human tumor lines including HeLa and A549,
which have been widely used for culture of wild type
adenovirus (Smith et al., 1986). In the retrovirus field,
production cell lines have been developed in which eachFig. 1. E1A functional domains and mutants used in this study. Schematic representa
CR2 and CR3, and domains involved in; binding of the cellular proteins p300/CB
susceptibility to tumor necrosis factor (TNF), and transcriptional activation of the ad
sequence by the E1Adl1101 and E1Adl1107 mutations are indicated.complementing function is supplied by an individual cassette
expressing a single retrovirus gene, with each cassette
introduced in a separate transfection step to further reduce
the potential for homologous recombination during vector
production (Palu et al., 2000).
In this paper, we describe a novel approach to
complementation of E1 function by use of a human tumor
cell line, A549, transformed with transgenes expressing
selected E1A and E1B activities. The salient features of this
approach include: sequential addition of E1A and E1B
expression cassettes for stable expression of select E1A and
E1B functions; use of the transformation defective E1Adl01/
07 mutant to reduce E1A induced toxicity in A549 cells;
definition of the E1B functions required for complementa-
tion with a genetic assay; and, complementation of E1B-
55K without E1B-19K to provide E1B function. The cell
lines resulting from this approach produce rAd-vectors
efficiently without detectable RCA.
Results
Virus production potential in selected cell lines was
assessed by infection with the replication competent virus
Ad5-dl309. A549 cells and HeLa cells produced virus at
558,000 and 444,000 particles/cell, respectively. Other lines
tested including, DLD-1, U87MG, MDA468 and IGROV-1,
all produced less than 120,000 particles/cell (data not
shown). 293 cells produced Ad5-dl309 virus at 139,000
particles/cell and rAd-h-gal virus at 127,000 particles/cells.
The production capacity for Ad5-dl309 in HeLa and A549
suggested that these human tumor lines were the best
candidates for use in development of E1 complementing cell
lines.
Complementation of E1A in A549 cells
A549 cells were chosen over HeLa cells for further
development because they do not contain papillomavirus
sequences (Oh et al., 2004). Expression of wild-type E1A istion of the 289R and 243R E1A proteins illustrating conserved regions 1 (CR1),
P and pRb, stimulation of cell cycle progression, induction of apoptosis and
enovirus early gene regions. Amino acid residues deleted in the wild-type E1A
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leads to apoptosis under serum-depleted conditions (Hubber-
stey et al., 2002). To limit the toxicities associated with E1A
expression in A549 cells, we tested several E1A mutants for
stable expression and complementation of E1 function for rAd-
vector production. The E1A mutants used, E1Adl1101,
E1Adl1107 and E1Adl01/07, carry deletions in regions of
E1A proteins that are required for induction of cell cycle
progression and apoptosis (Fig. 1) but do not compromise the
E1A transactivation domain required for stimulation of the
other early virus promoters. Specifically, the E1Adl1101 and
E1Adl1107 mutants are defective for binding to the cellular
proteins p300/CBP and pRb, respectively, whereas the
E1Adl01/07 mutant is defective for binding both cellular
proteins (Howe et al., 1990; Howe and Bayley, 1992).
Plasmids expressing either E1Adl1101, E1Adl1107,
E1Adl01/07 or wild-type E1A under control of an RSV
promoter were used to transfect A549 cells. The plasmids also
contained a neomycin resistance gene as a selectable marker.
Individual clones from pools of G418 resistant cells were
isolated and screened by infection with rAd-GFP. We visually
examined the level of GFP expression in 48 clones and then
selected five clones for further characterization. The production
capacity of each clone was determined by quantification of
rAd-GFP particles produced per cell as described in Materials
and methods. Results of the production assays (Fig. 2A) show
that the clones expressing either E1Awt, or E1Adl1101, had
low virus productivity. Clones isolated from the E1Adl1107
generally gave poor production yields, with the exception of
clone E1Adl1107-1 which had a yield of over 20,000 particles
per cell. In contrast, clones isolated from the E1Adl01/07Fig. 2. Production capacity for rAd-vectors and E1A protein expression in the A549
indicated E1A mutants (E1Adl1101, E1Adl1107, E1Adl01/07) or wild-type E1A (E
expressing the indicated E1A mutants or wildtype E1A, were determined by Westetransfection pool had the highest production yields as four of
the five clones assayed yielded particle concentrations between
20,000 and 30,000 per cell.
Measurement of E1A protein levels in E1A expressing A549
clones
E1A protein levels in the selected clones were determined
by Western blot analysis using an E1A-specific monoclonal
antibody (Harlow et al., 1985) that recognizes an epitope in the
C-terminal region (Fig. 2B). This epitope is unaffected by the
dl1101 and dl1107 mutations. Western analysis showed that
expression levels of E1A proteins varied greatly between the
clones. In addition, the amount of wild-type or mutant E1A
expressed did not correlate with the production yields. All
clones expressing wild-type E1A or the E1Adl1101 mutant
were inefficient producers regardless of the amount of E1A
protein expressed. Among the E1Adl1107 clones, only
E1Adl1107-1 was an efficient producer despite expressing
nearly undetectable levels of E1A protein. The E1Adl1107-1
clone was not further analyzed as it grew poorly, a character-
istic undesirable in a production cell line. The E1Adl01/07
clones also displayed various levels of protein with the best
producer clone E1Adl01/07-4 expressing lower levels as
compared to E1Adl01/07-5, which had comparatively high
levels.
Analysis of viral replication and apoptosis after infection
The E1Awt-2 and E1Adl01/07-5 cell clones, which
expressed similar levels of E1A proteins, were selected to-based clones. (A) Virus yield from sets of 5 cell clones selected to express the
1Awt). (B) Relative E1A protein levels in lysates from the A549-based clones,
rn blotting with antibodies specific for E1A or h-actin as a loading control.
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production yields. Because the E1Adl01/07-4 clone produced
viral particles more efficiently than any other line, it was also
selected for further characterization.
The ability of the A549-E1Awt-2 and two A549-E1Adl01/
07 clones to support replication of an E1-deleted virus rAd-h-
gal virus was analyzed by restriction enzyme digest of low
molecular weight DNA from infected cells. Restriction analysis
indicated that there were differences in the quantity and quality
of viral DNA isolated from the various cell lines (Fig. 3A). The
quality of rAd-h-gal DNA from the E1Adl01/07 cells was
comparable to 293 cell isolated viral DNA, although detected
at somewhat reduced levels particularly in the A549-E1Adl01/
07-5 clone. Extremely low levels of rAd-h-gal viral DNAs
were produced from the E1Awt-2 clone, and the DNA that was
isolated smeared on the agarose gel with DNA fragmentation
suggesting high levels of apoptosis in these cells.
Analysis of viral DNA produced from clone E1Awt-2
suggested that apoptosis could be occurring, potentially
limiting the amount of virus produced. We used a FITC-
VAD-FMK peptide to measure caspase activity by flowFig. 3. Characterization of the E1Awt-2, E1Adl01/07-4 and E1Adl01/07-5 clones fo
activity and protein level. (A) Low molecular weight DNA, isolated at 42 h afte
restriction enzyme and analyzed by agarose gel electrophoresis. (B) Percentage of
infection of the indicated cell types. (C) Luciferase activitymeasured in lysates of the in
E2F (E2F-luc) responsive promoters linked to the luciferase coding sequence. (D) Rel
h after infection with rAd-p53 (1  108 particles/ml), by Western blotting with p53 scytometry as an indicator of apoptotic cell death after infection.
As shown in Fig. 3B, almost half of the E1Awt-2cells were
apoptotic 20 h after infection, whereas apoptosis was not
induced in the E1Adl01/07-4 and E1Adl01/07-5 clones.
Together, these results suggest that viral infection of the
E1Awt-2 induces premature apoptosis, limiting viral DNA
replication and subsequent virus particle production.
Status of the E2F and p53 transcription factors in E1Awt and
E1Adl01/07 clones
Induction of apoptosis by E1A has been shown to be linked
to binding of pRb and p300/CBP, resulting in activation of the
E2F and p53 transcription factors. To measure E2F and p53
activity levels in the selected production cell clones, we
constructed reporter plasmids in which a luciferase gene was
placed under control of either a consensus p53 or E2F
promoters. p53 and E2F promoter activity was found to be
elevated in the E1Awt-2 clone (Fig. 3C). In contrast, p53 and
E2F activity levels in the E1Adl01/07-4 and E1Adl01/07-5
clones were similar to the control A549 cells.r viral DNA replication, induction of apoptosis after infection, E2F activity, p53
r rAdvector infection of the indicated cell types, was digested with the XhoI
apoptotic cells as determined by FITC-VAD-FMK labeling at 20 h after rAd
dicated cell clones after transfection of reporter plasmidswith the p53 (p53luc) or
ative p53 protein levels were measured in lysates of the indicated cell types, at 16
pecific monoclonal antibody and B-actin antibody as a loading control.
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determined by western blotting. A549 tumor cells express
wild type p53 (Ramachandra et al., 2001). However, in
preliminary experiments, significant levels of p53 protein
could not be detected by Western blotting extracts of A549
cells or the selected A549 production cell clones. p53 has been
shown to be highly unstable in A549 cells, likely as a result of
loss of ARF expression, and the subsequent hyperactivation of
the MDM2 feedback loop which promotes rapid p53 turnover
(Lu et al., 2002). Therefore, we used an Ad vector, rAd-p53, as
an exogenous source of p53 to measure the stability of p53 in
A549 cells and the selected clones. After infection with rAd-
p53, elevated levels of p53 were detected in the E1Awt-2 line
compared to control A549 cells and the E1A01/07-4 and
E1Adl01/07-5 lines (Fig. 3D).
Complementation of E1B in E1Adl01/07-4
Although the E1Adl01/07-4 clone was capable of produc-
ing replication defective adenovirus in small scale format, we
reasoned that yield could be further improved by complemen-
tation using E1B. To study the production yield of E1Adl01/
07-4 cells after E1B complementation E1Adl01/07-4 cells
were infected, at two different concentrations (1  108
particles/ml and 5  108 particles/ml), with a series of E1
adenovirus mutants to express E1B-19K and E1B-55K either
individually or together. We found that infection of E1Adl01/
07-4 cells with a virus that produces a non-functional truncated
E1A and wild-type E1B (Ad-NT1010) yielded virus compa-
rable to Ad5-dl309 (Fig. 4). In contrast, a mutant virus that
expressed E1A but no E1B (AdE1B) yielded only about
55,000 particles per cell after infection at both concentrations
of test virus. These results suggested that complementation of
E1B could significantly increase production yield. To further
define the contribution of the E1B region, viruses expressing
either E1B-19K (dl1520) or E1B-55K (AdE1B-19K) aloneFig. 4. Virus productivity after infection of E1Adl01/074 cells. Virus yield was me
E1B or NT1010 adenoviruses at two different concentrations (1e+8 particles/ml an
each adenovirus is indicated.were tested for growth on E1Adl01/07-4 cells. The E1B-19K
expressing virus productivity was considerably lower than
Ad5-dl309 whereas the E1B-55K expressing virus produced at
levels higher than Ad5-dl309.
These results suggested that addition of an E1B-55K gene
could increase the viral yield in the E1Adl01/07-4 cell line.
Use of only the E1B-55K coding sequences would further
reduce the possibility of generating RCA during rAd produc-
tion. We therefore used a selection plasmid in which the E1B-
55K gene was cloned under control of the CMV promoter
(pcDNA-55K) to complement E1B-55K function in E1Adl01/
07-4 cells. The sequence of the expression cassette in pcDNA-
55K was verified by DNA sequencing and expression of intact
E1B-55K protein was demonstrated by transient transfection in
HeLa cells (data not shown).
E1Adl01/07-4 cells were transfected with pcDNA-55K,
which also carried a hygromycin resistance marker, and
individual clones were selected from the drug-resistant pool
by dilution cloning. Clones were screened for E1B-55K
function using an assay that measured inhibition of a p53
responsive promoter (PRE) controlling GFP expression
carried in a replication defective adenovirus named rAd-
PRE-GFP. In cells expressing wild type p53, such as the
parental E1Adl01/07-4 line, GFP is expressed at high levels
from rAd-PRE-GFP. (Fig. 5A). In contrast, expression of
GFP from rAd-PRE-GFP is low in cells such as 293, which
also express E1B-55K and wild-type p53. Several clones
including E1Adl01/07-4-E1B-55K-2 were selected using this
assay and further characterized for E1B-55K expression and
virus production.
Similar levels of E1B-55K protein were detected by
immunoprecipitation, with the E1B-55K specific monoclonal
antibody 2A6, in cell lysates from all of the selected clones
(Fig. 5B) and one clone E1Adl01/07-4-E1B-55K-2, hereafter
designed SL0003, was selected for further characterization
based on its growth properties and virus production.asured from E1Adl01/07-4 cells infected with Ad5-dl309, dl1520, E1B-19K,
d 5e+8 particles/ml). The expression status of E1B-19K, E1B-55K and E1A for
Fig. 5. Functional screening assay for E1B-55K expression in E1Adl01/07-4 cells. (A) E1Adl01/07-4, E1Adl01/07-4-E1B-55K-2 and 293 cells were infected with
rAd-PRE/GFP, which contains a GFP expression cassette driven by a p53-responsive promoter, or rAd-GFP in which GFP expression is driven by the CMV
promoter. (B) E1B-55K detected by immunoprecipitation/Western blotting of lysates from 6 selected E1Adl01/07-4 -E1B-55K clones.
Table 1
Virus yield from SL0003 cells
SL0003 passage no. Particle no. (TSD)
5 88,800 T 2800
15 105,600 T 3700
20 93,000 T 2800
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production and therefore the virus growth capacity of
SL0003 cells was evaluated during 20 cell culture passages.
Table 1 shows that SL0003 cells assayed at passage 5, 15 and
20 produced rAd-h-gal virus at an average of about 96,000
particles per cell.
RCA testing of virus produced in SL0003 cells
One of the goals in developing SL0003 cells was to
reduce the possibility of RCA generation during production
of Ad-vectors. To test for RCA generation during
production, rAd-h-gal was serially passaged in either
SL0003 or 293 cells grown in cell factories containing
approximately 1  109 cells, using a RCA-free virus lot
as the initial inoculum (see Materials and methods). Thebioassay used for detection of RCA had a sensitivity of 1
particle of wild-type virus per 1.7  1010 particles of rAd-
h-gal (see Materials and methods). Wild type Ad5 virus
was used as a positive control in these assays. RCA was
measured using 1  1011 particles of rAd-h-gal virus
produced from either SL0003 or 293 cells. After 5 serial
passages, RCA was detected in rAd-h-gal virus purified
from 293 cells, but no RCA was detected in rAd-h-gal
purified from SL0003. PCR analysis confirmed that the
J.A. Howe et al. / Virology 345 (2006) 220–230226virus detected in the RCA assay arose from recombination
rather than contamination by Ad5 (data not shown).
Discussion
We have established a new rAd production cell line, SL0003,
using selected viral and cellular functions to complement Ad
replication in A549 tumor cells. Optimization of E1 comple-
mentation in SL0003 was achieved using sequential addition of
separate E1A and E1B expression cassettes. In SL0003, the
E1Adl01/07 mutant gene was constitutively expressed to
provide E1A function and to reduce cellular toxicity associated
with wild-type E1A. E1B function in SL0003 was provided by
constitutive expression of the E1B-55K gene; the E1B-19K gene
was not included. Separation of the E1A and E1B cassettes, use
of a mutant E1A and only E1B-55K eliminates the possibility of
reconstitution of an intact E1 region through either homologous
or non-homologous recombination and resultant generation of
RCA. Although the Ad sequences used for complementation in
SL0003 are extensively modified compared to the wild-type E1
sequence in 293 cells, SL0003 was shown to produce rAd
vectors at levels comparable to 293 without generation of
detectable RCA.
SL0003 cells were established from a human tumor line,
whereas the 293 and PER.C6 producer cell lines were
established by adenovirus E1A-induced immortalization of
primary human cells. Constitutive expression of the E1 proteins,
especially E1A, has proven difficult in established cell lines
(Imler et al., 1996). For example, E1A has been shown to
suppress cell growth and induce anoikis (Frisch, 1991; Frisch
and Mymryk, 2002; Mymryk et al., 1994; Rao et al., 1992).
Imler et al. used regulated induction of E1 as a strategy to avoid
toxicity associated with constitutive expression of E1A, allow-
ing generation of rAd producer cell lines based on A549 cells
(Imler et al., 1996). Production yields of rAd-vectors from these
Gal4-inducible producer cell lines, which expressed E1A and
E1B-19K but not E1B-55K, were reported to be 5- to 10-fold
lower than from 293 cells (Imler et al., 1996).
An alternative approach to overcome the toxicity associated
with wild-type E1A in tumor cells was to use mutant E1A genes
to provide only the required functions. Previous work by our
group and others has demonstrated that adenoviruses carrying
the E1Adl01/07 mutation, or similar mutations affecting
induction of cellular DNA synthesis and apoptosis, can replicate
efficiently in human tumor cell lines but are attenuated for viral
growth in normal human cells (Balague et al., 2001; Doronin et
al., 2000; Howe et al., 2000). These results demonstrate that
tumor cells, in which cell cycle control is aberrant, can
complement the ability of mutated E1A genes to induce cellular
DNA synthesis, a function required for efficient adenoviral
growth in quiescent normal cells. In the present study, we took
advantage of the unique properties of E1Adl01/07, which has
mutations affecting cellular DNA synthesis and apoptosis but
still carries the wild-type CR3 domain which transactivates early
viral promoters required for the initial phase of lytic growth
(Winberg and Shenk, 1984). Consistent with the growth
properties of the E1A mutant viruses noted above, A549 clonesthat constitutively expressed the E1Adl01/07 gene supported
replication of E1-deleted rAd vectors at levels higher than clones
expressing wild-type E1A or the single mutations E1Adl1101 or
E1Adl1107. In agreement with previous observations on E1A
toxicity, A549 clones expressing wild-type E1Awere especially
sensitive to apoptosis following infection with E1-deleted rAd
vectors and viral yields were extremely low.
E1A gene transfer has been reported to increase the
sensitivity of cells to toxicity induced by TNF-a (Shisler et
al., 1996) and chemotherapeutics (Ueno et al., 2000; Zhou et
al., 2001), suggesting that E1A induces a pro-apoptotic state
that can render cells highly sensitive to death stimuli (Lee et al.,
2003). Increased TNF-a susceptibility was observed in NIH
3T3 cells expressing wild-type E1A or E1A mutants that could
stimulate cellular DNA synthesis, but not in cells expressing
E1Adl01/07 or other mutants that did not induce cellular DNA
synthesis and consequently apoptosis (Shisler et al., 1996). The
rapid induction of apoptosis in clone A549E1Awt-2 suggests
that early events in viral infection may supply death signals that
can be recognized by A549 cells expressing wild-type E1A but
not E1Adl01/07. Recent studies have shown that retroviral
expression of E1A can establish a pro-apoptotic state in cells
through stimulation of the E2F pathway, leading to accumu-
lation of caspase proenzymes and an increased susceptibility to
cell death signals that trigger caspase activation and apoptosis
(Nahle et al., 2002).
Apoptosis in adenovirus-infected cells can be stimulated
though p53-dependent and p53-independent pathways (Teo-
doro et al., 1995). We found that both E2F and p53 pathways
were stimulated in the A549wt-2 clone as compared to the
A549E1Adl01/07 clones in which E2F and p53 transcriptional
activity was similar to the parental A549 cells. The stimulation
of the E2F and p53 pathways by wild-type E1A was not
sufficient to induce apoptosis in the A549wt-2 clone, but likely
contributed to the increased sensitivity of these cells to death
stimuli. Consistent with this hypothesis, we found that
A549E1Awt-2 cells could be driven into apoptosis by low
levels of cycloheximide, but that A549E1Adl01/07 clones
were unaffected by this treatment (data not shown). Further
work will be required to define the apoptotic signals associated
with adenovirus infection. Possible mechanisms include virus
entry and internalization, which has been shown to activate the
PI3K and MAPK pathways (Meier and Greber, 2003), viral
DNA replication, or expression of viral genes such as E4orf4
(Marcellus et al., 1996).
The E1 region used for complementation of E1-deleted
adenoviruses in 293 cells and PERC.6 cells includes the entire
E1B transcription unit, which encodes two major proteins: E1B-
19K and E1B-55K. In adenovirus replication, the E1B-19K and
E1B-55K proteins function in the early lytic cycle to limit E1A-
induced apoptosis (Querido et al., 1997; Rao et al., 1992; White
et al., 1991). In addition, E1B-55K functions in the late phase to
stimulate the accumulation and translational of viral late mRNAs
(Babiss et al., 1985; Harada and Berk, 1999). E1B has also has
been shown to collaborate with E1A in transforming primary
cells [for review, see (Branton et al., 1985)], and specifically
protects against E1A sensitization to apoptosis (White et al.,
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because it reduced sensitivity to apoptosis during vector
production. We next sought to determine whether both E1B
genes were needed for rAd vector complementation in the
E1Adl01/07-expressing A549 cell line. Analysis of virus yield
using a series of E1B-mutant viruses showed that in
A549E1Adl01/07-4 cells, expression of E1B-55K alone was
sufficient for production of the mutant viruses at wild-type
levels. These results suggested that efficient complementation
could be achieved in A549 cells by E1Adl01/07 plus E1B55K,
which was subsequently demonstrated in the SL0003 line. The
yield of rAd vectors from the SL0003 line was similar to that
obtained from 293 cells, without generation of detectable RCA.
In conclusion, this study demonstrates that efficient pro-
duction of E1-deleted rAd vectors can be achieved by matching
complementing functions of transformed cells with stable
expression of selected viral genes.
Materials and methods
Cell culture
293 (ATCC #CRL-1573), A549 (ATCC #CCL-185) and
HeLa (ATCC #CCL-2) cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). All cell lines
were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% (vol/vol) fetal bovine serum (JRH
Biosciences, Lenexa, KS), 1% (vol/vol) antibiotic–antimycotic
solution (Cellgro, Kansas, MO) and 1 mM sodium pyruvate
(BioWhittaker, Inc., Walkersville, MD).
Plasmids
The Ad5 wild-type E1A gene, and E1A sequences containing
the E1Adl1101, E1Adl1107 and E1Adl01/07 mutations were
cloned by standard procedures from pXC1 (McKinnon et al.,
1982) or Ad-dl01/07 (Howe et al., 1990) into the RSV promoter/
SV40 polyA expression cassette of pRc/RSV-Neo (Invitrogen,
Carlsbad CA) to create pRc/RSV-E1Awt , pRc/RSV-
E1Adl1101, pRc/RSV-E1Adl1107 and pRc/RSV-E1Adl01/07.
pcDNA3.1-E1B-55K, was constructed by cloning the E1B-55K
gene from pXC1 using PCR into the CMV promoter/BGH poly
A expression cassette of pcDNA3.1-hygro (Invitrogen Carlsbad,
CA). p53con-luc contains 4 consensus p53 binding sites, and a
TATA box from the simian virus-40 (SV40) early promoter
(Ramachandra et al., 2001), upstream of the luciferase gene in
pGL3-basic (Promega, Madison, WI). pE2F-luc contains 4
copies of the E2F binding sites from the adenovirus early region
2 promoter and an SV40 TATA box upstream of the luciferase
gene in pGL3-basic.
Viral constructs
rAd-h-gal and rAd-GFP are E1/E3 deleted adenovirus
vectors with expression cassettes inserted in the E1-deletion in
which the h-galactosidase (h-gal) gene, or green fluorescent
protein (GFP) gene, are under control of the constitutively activeCMV immediate early promoter (Cheney et al., 1998; Wills et
al., 1994). The p53 reporter rAd-PRE-GFP contains an
expression cassette in the E3-deletion in which a p53-response
element (Ramachandra et al., 2001) regulates expression of GFP.
Ad5-dl309 (Jones and Shenk, 1979) was used as a wild-type
control virus, and the Ad5-dl309 based mutant viruses E1B/
19K, which does not produce the E1B-19K protein (Marcellus
et al., 1996), and NT1010, which has a large deletion in the E1A
region (Whyte et al., 1989), have been described previously.
dl1520 (Barker and Berk, 1987) is a chimeric adenovirus (Ad2
and Ad5-dl309) containing a deletion in the E1B coding region
(Ad5 coordinates 2496–3233) and a stop codon at the third
codon of E1B-55K. The Ad-E1B virus was constructed by
removing the E1B coding region in plasmid pXC1 byEcoNI and
BglII digestion, Klenow fill in and blunt end ligation to create
pXC1-E1B. Ad sequence containing the mutated E1B region
was transferred from pXC1-E1B into a larger transfer plasmid
pTG9530 (Transgene S.A., Strasbourg), to create pTG9530-
E1B. Homologous recombination in E. coli strain BJ5183
(Chartier et al., 1996) was used to generate infectious Ad-E1B
adenoviral DNA by transformation of pTG9530-E1B and viral
plasmid pTG4213-Ad5-dl309. The resulting Ad-E1B plasmid
was isolated and transfected into 293 cells to generate virus.
All viruses were purified by column chromatography
using a method described previously (Huyghe et al., 1995).
Particle concentrations were estimated by an ion exchange
HPLC-based method (RQ-HPLC) that determines concentra-
tions of intact adenovirus particles relative to an internal
adenovirus standard (Shabram et al., 1997).
Selection of A549 cell clones expressing E1Awt, E1A-mutant
proteins and E1B-55K
For selection of clones expressing E1Awt or E1A-mutant
proteins plasmids pRc/RSV-E1Awt, pRc/RSV-E1A1101, pRc/
RSV-E1A1107 and pRc/RSV-E1A01/07 were transfected into
A549 cells using Superfect reagent (Qiagen, Valencia CA). After
incubation for two days selection was initiated in growth
medium containing 350 Ag/ml neomycin (Invitrogen, Carlsbad,
CA). Drug-resistant colonies from the cultures transfected with
the E1Awt, or E1A-mutant selection plasmids, were trypsinized,
established as cell pools, and dilution cloned in 96-well plates.
Selection in culture medium containing neomycin was carried
out 3 more weeks, after which 48 individual clones from each
transfection were expanded and screened for virus production
potential.
A549-E1Adl01/07-4 based cell lines were engineered to
express E1B-55K using the same procedure except that A549-
E1Adl01/07-4 cells were transfected with pcDNA3.1-E1B-
55K and selected in 350 Ag/ml hygromycin (Invivogen, San
Diego, CA).
Screening procedures for cells clones
The virus production potential of A549-based clones
expressing E1Awt, or E1A-mutant proteins, was assessed by
infecting cells that were plated on 6-well plates with rAd-
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estimated by monitoring green fluorescence protein intensity
and cytopathic effect (CPE). For screening E1A01/07-4
based clones established by transfection with pcDNA3.1-
E1B-55K cells were infected with rAd-PRE-GFP (1  108
particles/ml) and clones with low GFP intensity, suggesting
reduced p53 activity, and robust CPE were chosen for
further characterization.
Virus production in the selected clones was determined by
measuring the number of particles produced on a per cell basis.
For this assay, cells were infected with rAd vector at 5  108
particles/ml, and at the time of infection cells in duplicate
plates or flasks were trypsinized and counted using a Coulter
Counter (Beckman-Coulter, Miami, FL). At a time point when
the infection was complete (3–4 days) cells and media were
collected, freeze/thawed 3 times and centrifuged to remove
cellular debris. The particle concentration in the cleared lysates
was determined using anion-exchange high-performance liquid
chromatography (Shabram et al., 1997).
Western blotting analysis to determine E1A protein levels
Whole cell protein lysates were prepared by incubation of
the indicated cells in lysis A buffer (50 mM Tris [pH 8.0],
150 mM NaCl, 0.5% [vol/vol] IGEPAL CA-630 [Sigma, St.
Louis, MO] and protease inhibitor cocktail [Roche, India-
napolis, IN]) followed by centrifugation. Total protein
concentration in the lysates was determined by the Bio-
Rad protein assay (Bio-Rad, Hercules, CA) and 50 Ag
aliquots were separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) with gradient
(4%–12%) NUPAGE gels (Invitrogen, Carlsbad, CA). After
transfer onto PVDF membranes (Invitrogen, Carlsbad, CA),
western detection was performed using antibodies specific
for E1A (M73, Calbiochem, La Jolla, CA) or B-actin
(Sigma-Aldrich, St. Louis, MO). Binding patterns were
determined by incubating the membranes with horseradish
peroxidase-conjugated anti-mouse immunoglobulin G and M
(Roche, Indianapolis, IN) and detected by enhanced chemi-
luminescence (Amersham BioSciences, Piscataway, NJ).
Analysis of viral DNA
Small molecular weight DNA was isolated from cells
infected with rAd-h-gal (1  108 particles/ml) on 6-well
plates at the indicated time points using a modified Hirt
extraction (Hirt, 1967). Infected cells were harvested by
scraping and lysed in TNE buffer [500 mM NaCl, 10 mM
Tris (7.5), 10 mM EDTA, 1% SDS, 0.5 mg/ml proteinase K
(Sigma), 0.25 mg/ml, pronase E (Sigma)]. After a freeze–
thaw cycle lysates were cleared by centrifugation, extracted
with a phenol:chloroform mixture (Sigma, St. Louis, MI)
and ethanol precipitated. The nucleic acid pellets were
suspended in 60 Al of TE containing RNase (Ambion,
Austin, TX), after which 12 Al samples were restricted with
XhoI, separated on 1% agarose gels. DNA restriction
patterns were visualized by ethidium bromide staining.Flow cytometric determination of apoptosis with
FITC-VAD-FMK
E1Awt, E1A-mutant clones and A549 control cells were
plated on 6-well plates at 1.5  105 cells per well and infected
at 24 h with rAd-h-gal (1  108 particles/ml). At 20 h after
infection, 5 AM CaspACE FITCTM-VAD-FMK (Promega,
Madison, WI) was added directly to the culture medium. After
incubation for 20 min at 20 -C the cells were trypsinized,
washed 2 times with PBS and fixed in 0.5% formaldehyde for
30 min at 20 -C. Flow cytometry analysis was performed using
an FACSCalibur (Becton Dickinson, San Jose, CA) and
fluorescence was measured at 530 nm (excitation of 488 nm).
Luciferase assays
Lysates of cells transfected with reporter plasmids using
Superfect (Qiagen, Valencia, CA), were mixed with the
reconstituted luciferase substrate (Promega, Madison, WI)
according to the manufacturer’s specifications. Luciferase
activity of each lysate was determined using an Analyst AD
(Molecular Devices, Sunnyvale, CA).
Immunoprecipitation of E1B-55K
Protein lysates (1 mg total protein) prepared as described
above were pre-cleared with protein-G sepharose beads
(Amersham BioSciences, Piscataway, NJ) and incubated with
5 Ag of the E1B-55K specific mouse monoclonal antibody,
2A6 (Sarnow et al., 1982). E1B-55K–immunoglobulin com-
plexes were purified on protein-G sepharose, washed exten-
sively with lysis buffer, and incubated with SDS-PAGE sample
buffer containing reducing agent (Invitrogen, Carlsbad, CA).
The samples were separated on SDS-PAGE gels and E1B-55K
protein was detected by Western blot as described above, using
the 2A6 monoclonal antibody.
Serial passage of an E1-deleted rAd-vector in 293 or SL0003
The rAd-h-gal virus used for serial passage was plaque
purified three times, propagated using SL0003 cells grown in a
cell factory (Nunc A/S, Kamstrupvej, Denmark) and after
chromatographic purification the resulting virus stock, called
rAd-h-gal (p0), tested free of replication competent adenovirus
(RCA) using the 21-day bioassay described below. For serial
passage infection, cell factories containing 293 or SL0003 were
infected with purified rAd-h-gal (p0) at 5  108 particles/ml.
Cell lysates were prepared when the infections were complete
and were used to infect fresh 293 or SL0003 cells seeded in cell
factories to prepare the passage 1 lysate. Lysates for infection of
passages 2 to 5 were prepared similarly, and at passage 5, virus
was purified by column chromatography as described above.
Assay for RCA
A modified bioassay based on a previously described
protocol (Zhu et al., 1999) was used to detect RCA using 1 
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or SL0003. For the initial RCA bioassay infection 10-T225
flasks were seeded with 1 107 cells of A549 cells. At 24 h after
seeding, the cells were infected with 1 1010 particles per flask
of rAd-h-gal which was prepared from 293 or SL0003 cells.
After 3 days, a cell lysate was prepared from the infected A549
cells and used to infect a second set of flasks that had been
seeded with 3 106 A549 cells. For the second infection, half of
the rAd-h-gal lysates from the first infections were used to infect
5-T225 flasks. At 12 days after, the initial infection lysates from
the second round of infections were prepared and used to infect
10-flasks seeded with 3  106 A549 cells. The third infection
procedure was preformed as for the second infection and
incubated for 9 more days. If CPE was observed during the
bioassay, low molecular weight DNA was isolated from
approximately 1  107 cells for viral DNA analysis. Controls
included 1  1011 virus particles of rAd-h-gal spiked with 6
virus particles of Ad5 wild-type, or 6 virus particles of Ad5 wild-
type alone using the infection procedure described above. Both
controls were required to produce CPE during the 21-day
infection window for a positive assay.
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